Evidence map›Paper›PMID 25644061›Full record

ArticleMolecular cancer2015

SOX4 interacts with EZH2 and HDAC3 to suppress microRNA-31 in invasive esophageal cancer cells.

Rainelli B Koumangoye, Thomas Andl, Kenneth J Taubenslag, Steven T Zilberman, Chase J Taylor, Holli A Loomans, Claudia D Andl

Open access · goldAbstract read
In one paragraph

Article in Molecular cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed
6.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 137 citations in OpenAlex.

  1. Esophageal cancer: from pathogenesis to precision therapies.Signal transduction and targeted therapy · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. HEYL-mediated activation of LAMA3 influences radiotherapy response in esophageal cancer.Esophagus : official journal of the Japan Esophageal Society · 2025
    Article
  7. Review
  8. Article
  9. SOX on tumors, a comfort or a constraint?Cell death discovery · 2024
    Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. miR-31-5p-Oncology letters · 2022
    Article
  17. Article
  18. Article
  19. Article
  20. Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Rainelli B KoumangoyeDepartment of Surgery, 2213 Garland Ave. 10445 MRB IV, Nashville, TN, 37232-6840, USA. rainelli.koumangoye@vanderbilt.edu.
Thomas AndlDivision of Dermatology, Department of Medicine, 21st Ave South, A-2310 Medical Center North, Nashville, TN, 37232-6840, USA. thomas.andl@vanderbilt.edu.
Kenneth J TaubenslagDepartment of Surgery, 2213 Garland Ave. 10445 MRB IV, Nashville, TN, 37232-6840, USA. kenneth.j.taubenslag@Vanderbilt.Edu.
Steven T ZilbermanDepartment of Surgery, 2213 Garland Ave. 10445 MRB IV, Nashville, TN, 37232-6840, USA. steven.t.zilberman@Vanderbilt.Edu.
Chase J TaylorDepartment of Surgery, 2213 Garland Ave. 10445 MRB IV, Nashville, TN, 37232-6840, USA. claudia.andl@vanderbilt.edu.
Holli A LoomansDepartment of Cancer Biology, 2213 Garland Ave. 10445 MRB IV, Nashville, TN, 37232-6840, USA. holli.a.loomans@vanderbilt.edu.
Claudia D AndlDepartment of Surgery, 2213 Garland Ave. 10445 MRB IV, Nashville, TN, 37232-6840, USA. claudia.andl@vanderbilt.edu.
Baylor Medical Center at Garland · US

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8M
VANDERBILT UNIVERSITY CTSA FOR PEDIATRIC RESEARCHUL1RR024975 · NCRR · VANDERBILT UNIVERSITY · PI BERNARD, GORDON RAPHAEL · 2007 to 2011
$45.7M
The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
The role of microRNA miR-31 in skin biologyR01AR061474 · NIAMS · VANDERBILT UNIVERSITY · PI ANDL, THOMAS · 2011 to 2015
$1.7M
The role of Activin A signaling in esophageal cell invasionR01DK094900 · NIDDK · VANDERBILT UNIVERSITY · PI ANDL, CLAUDIA D · 2012 to 2016
$1.6M
Mechanisms of epithelial-mesenchymal crosstalk during esophageal cell invasionR03DK091491 · NIDDK · VANDERBILT UNIVERSITY · PI ANDL, CLAUDIA D · 2012 to 2013
$153k
NCATS NIH HHS 2 UL1 TR000445-06NCATS NIH HHS UL1 TR000445NCI NIH HHS P30 CA068485NCI NIH HHS P30 CA68485NCRR NIH HHS UL1 RR024975NCRR NIH HHS UL1 RR024975-01NIAMS NIH HHS R01 AR061474NIDDK NIH HHS DK091491NIDDK NIH HHS DK94900NIDDK NIH HHS P30 DK058404NIDDK NIH HHS R01 DK094900NIDDK NIH HHS R03 DK091491
6 · The paper itself

Abstract

backgroundTumor metastasis is responsible for 90% of cancer-related deaths. Recently, a strong link between microRNA dysregulation and human cancers has been established. However, the molecular mechanisms through which microRNAs regulate metastasis and cancer progression remain unclear.

methodsWe analyzed the reciprocal expression regulation of miR-31 and SOX4 in esophageal squamous and adenocarcinoma cell lines by qRT-PCR and Western blotting using overexpression and shRNA knock-down approaches. Furthermore, methylation studies were used to assess epigenetic regulation of expression. Functionally, we determined the cellular consequences using migration and invasion assays, as well as proliferation assays. Immunoprecipitation and ChIP were used to identify complex formation of SOX4 and co-repressor components.

resultsHere, we report that SOX4 promotes esophageal tumor cell proliferation and invasion by silencing miR-31 via activation and stabilization of a co-repressor complex with EZH2 and HDAC3. We demonstrate that miR-31 is significantly decreased in invasive esophageal cancer cells, while upregulation of miR-31 inhibits growth, migration and invasion of esophageal adenocarcinoma (EAC) and squamous cell carcinoma (ESCC) cell lines. miR-31, in turn, targets SOX4 for degradation by directly binding to its 3'-UTR. Additionally, miR-31 regulates EZH2 and HDAC3 indirectly. SOX4, EZH2 and HDAC3 levels inversely correlate with miR-31 expression in ESCC cell lines. Ectopic expression of miR-31 in ESCC and EAC cell lines leads to down regulation of SOX4, EZH2 and HDAC3. Conversely, pharmacologic and genetic inhibition of SOX4 and EZH2 restore miR-31 expression. We show that SOX4, EZH2 and HDAC3 form a co-repressor complex that binds to the miR-31 promoter, repressing miR-31 through an epigenetic mark by H3K27me3 and by histone acetylation. Clinically, when compared to normal adjacent tissues, esophageal tumor samples show upregulation of SOX4, EZH2, and HDAC3, and EZH2 expression is significantly increased in metastatic ESCC tissues.

conclusionsThus, we identified a novel molecular mechanism by which the SOX4, EZH2 and miR-31 circuit promotes tumor progression and potential therapeutic targets for invasive esophageal carcinomas.

Indexed as

Gene Expression Regulation, Neoplastic3' Untranslated RegionsBase SequenceBinding SitesCell Line, TumorDown-RegulationEnhancer of Zeste Homolog 2 ProteinEpigenesis, GeneticEsophageal NeoplasmsHistone Deacetylase 3Histone DeacetylasesHumansMicroRNAsNeoplasm InvasivenessPolycomb Repressive Complex 2Protein Binding3' Untranslated RegionsEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanHistone Deacetylase 3Histone DeacetylasesMicroRNAsMIRN31 microRNA, humanPolycomb Repressive Complex 2Repressor ProteinsSOX4 protein, humanSOXC Transcription Factors

Identifiers

PMID25644061
PMCPMC4374188
OpenAlexW2118472712

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.